KR101567969B1 - 벤질페닐 시클로헥산 유도체 및 이의 사용 방법 - Google Patents

벤질페닐 시클로헥산 유도체 및 이의 사용 방법 Download PDF

Info

Publication number
KR101567969B1
KR101567969B1 KR1020107015420A KR20107015420A KR101567969B1 KR 101567969 B1 KR101567969 B1 KR 101567969B1 KR 1020107015420 A KR1020107015420 A KR 1020107015420A KR 20107015420 A KR20107015420 A KR 20107015420A KR 101567969 B1 KR101567969 B1 KR 101567969B1
Authority
KR
South Korea
Prior art keywords
phenyl
diabetes
chloro
rti
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107015420A
Other languages
English (en)
Korean (ko)
Other versions
KR20100098690A (ko
Inventor
위안웨이 첸
쿤 펭
릴리 장
빈후아 엘브이
바이후아 쉬
지아지아 동
지얀 두
얀 펭
게 수
바산타쿠말 라자판
브라이언 시드
Original Assignee
테라코스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테라코스, 인코포레이티드 filed Critical 테라코스, 인코포레이티드
Publication of KR20100098690A publication Critical patent/KR20100098690A/ko
Application granted granted Critical
Publication of KR101567969B1 publication Critical patent/KR101567969B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
KR1020107015420A 2007-12-13 2008-12-11 벤질페닐 시클로헥산 유도체 및 이의 사용 방법 Expired - Fee Related KR101567969B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1351707P 2007-12-13 2007-12-13
US61/013,517 2007-12-13

Publications (2)

Publication Number Publication Date
KR20100098690A KR20100098690A (ko) 2010-09-08
KR101567969B1 true KR101567969B1 (ko) 2015-11-10

Family

ID=40754059

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107015420A Expired - Fee Related KR101567969B1 (ko) 2007-12-13 2008-12-11 벤질페닐 시클로헥산 유도체 및 이의 사용 방법

Country Status (16)

Country Link
US (1) US8129434B2 (enExample)
EP (1) EP2230907B1 (enExample)
JP (1) JP5507464B2 (enExample)
KR (1) KR101567969B1 (enExample)
CN (1) CN101938902B (enExample)
AR (2) AR071268A1 (enExample)
AU (1) AU2008335080B2 (enExample)
BR (1) BRPI0819930A2 (enExample)
CA (1) CA2707909C (enExample)
IL (1) IL206234A0 (enExample)
NZ (1) NZ586639A (enExample)
RU (1) RU2505521C2 (enExample)
TW (1) TWI426081B (enExample)
UA (1) UA101004C2 (enExample)
WO (1) WO2009076550A1 (enExample)
ZA (1) ZA201004400B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9061060B2 (en) * 2008-07-15 2015-06-23 Theracos Inc. Deuterated benzylbenzene derivatives and methods of use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
KR101961884B1 (ko) * 2011-05-26 2019-03-25 티에프켐 아릴, 헤테로아릴, 오-아릴 및 오-헤테로 아릴 족 카르바슈가
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103570671B (zh) * 2012-09-26 2016-03-30 上海天慈生物谷生物工程有限公司 一种降糖化合物及其制法和应用
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
ES2859905T3 (es) 2013-12-17 2021-10-04 Boehringer Ingelheim Vetmedica Gmbh Inhibidores de SGLT2 para el tratamiento de trastornos metabólicos en animales felinos
US10759729B2 (en) * 2016-11-07 2020-09-01 The Chinese University Of Hong Kong Compounds for treating diabetes
CN116785268A (zh) * 2022-03-14 2023-09-22 江苏万邦生化医药集团有限责任公司 一种sglt-2抑制剂的药物组合物

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE870404A (fr) * 1977-09-13 1979-03-12 Pfizer Cycloalcanones et cycloalcanols substitues en position 3 par un groupe 2-hydroxyphenyle substitue en position 4 et composition pharmaceutique les contenant
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
EP0671953A4 (en) 1992-11-13 1996-01-10 Univ Ohio State Res Found C-GLYCOSIDE ANALOG OF N- (HYDROXYPHENYL) RETINAMIDE-O-GLUCURONID.
WO1998031697A1 (en) 1997-01-15 1998-07-23 Sankyo Company, Limited Aryl c-glycoside compounds and sulfated esters thereof
US6069238A (en) 1998-09-30 2000-05-30 Eli Lilly And Company Spirocyclic C-glycosides
US7407978B2 (en) 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
WO2002040458A1 (en) 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Isoxazole derivatives
TWI255817B (en) 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
CA2444481A1 (en) 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
WO2003020737A1 (en) 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
AU2003254847B2 (en) 2002-08-08 2009-06-04 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
PL375298A1 (en) 2002-08-09 2005-11-28 Taisho Pharmaceutical Co, Ltd. Process for selective production of aryl 5-thio-beta-d-aldohexopyranosides
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
CN101260130A (zh) 2003-01-03 2008-09-10 布里斯托尔-迈尔斯斯奎布公司 制备c-芳基葡糖苷sglt2抑制剂的方法
ES2567571T3 (es) 2003-03-14 2016-04-25 Astellas Pharma Inc. Derivados de C-glucósido y sales de los mismos
JP2004300102A (ja) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
TW200524951A (en) 2003-08-01 2005-08-01 Janssen Pharmaceutica Nv Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
CA2549015A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted fused heterocyclic c-glycosides
EP2514756B1 (en) 2003-08-01 2014-12-17 Mitsubishi Tanabe Pharma Corporation Novel compounds having inhibitory activity against sodium-dependant glucose transporter
DE502004008951D1 (de) 2003-08-26 2009-03-19 Boehringer Ingelheim Pharma Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
DE10361133A1 (de) 2003-12-22 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Glucopyranosyloxy-substituierte Aromaten, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7371732B2 (en) 2003-12-22 2008-05-13 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
EP1721904A4 (en) 2004-03-04 2010-07-14 Kissei Pharmaceutical HETEROCYCLIC DERIVED FADE; MEDICAL COMPOSITION CONTAINING THE DERIVATIVE AND MEDICAL USE
PL1730131T3 (pl) 2004-03-16 2012-10-31 Boehringer Ingelheim Int Glukopiranozylo-podstawione pochodne benzenu, środki lecznicze zawierające te związki, ich zastosowanie i sposób ich wytwarzania
CA2560005A1 (en) 2004-03-31 2005-10-13 Kissei Pharmaceutical Co., Ltd. Phenol derivative, medicinal composition containing the same, and medicinal use thereof
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CN101010276B (zh) * 2004-07-26 2011-01-12 中外制药株式会社 环己烷衍生物、其前体药物及其盐、以及含有它的糖尿病治疗药
TW200606129A (en) * 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
WO2006010557A1 (de) 2004-07-27 2006-02-02 Boehringer Ingelheim International Gmbh D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006018150A1 (de) * 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
CA2581922A1 (en) 2004-09-29 2006-04-06 Kissei Pharmaceutical Co., Ltd. 1-(.beta.-d-glycopyranosyl)-3-substituted nitrogenous heterocyclic compound, medicinal composition containing the same, and medicinal use thereof
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP1828216B1 (en) 2004-12-16 2008-09-10 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
JP5264183B2 (ja) 2005-02-23 2013-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換（（ヘテロ）アリールエチニル−ベンジル）−ベンゼン誘導体及びナトリウム依存性グルコース共輸送体２（ｓｇｌｔ２）インヒビターとしてのそれらの使用
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
DE602006011453D1 (de) 2005-04-15 2010-02-11 Boehringer Ingelheim Pharma Glucopyranosyl-substituierte (heteroaryloxy-benzyl)-benzen-derivate als sglt-inhibitoren
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007000445A1 (en) 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
EP1910390B1 (en) 2005-07-27 2010-05-19 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted ((hetero)cycloalyklethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
ATE484499T1 (de) 2005-08-30 2010-10-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
BRPI0615882A2 (pt) 2005-09-08 2011-05-31 Boehringer Ingelheim Int formas cristalinas de 1-cloro-4-(beta-d-glicopiranos-1-il)-2-(4-etinil-benzil)- benzeno, métodos para sua preparação e o uso para preparar medicamentos do mesmo
TWI370818B (en) 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
BRPI0711949A2 (pt) 2006-05-19 2012-01-17 Taisho Pharmaceutical Co., Ltd. composto c-fenil glicitol
WO2007140191A2 (en) * 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
AU2008232419B2 (en) 2007-04-02 2013-06-20 Theracos, Inc. Benzylic glycoside derivatives and methods of use
NZ583369A (en) 2007-08-23 2011-08-26 Theracos Inc Benzylbenzene derivatives and methods of use

Also Published As

Publication number Publication date
CA2707909C (en) 2016-10-18
IL206234A0 (en) 2010-12-30
WO2009076550A1 (en) 2009-06-18
EP2230907A4 (en) 2015-04-08
UA101004C2 (en) 2013-02-25
US8129434B2 (en) 2012-03-06
JP5507464B2 (ja) 2014-05-28
ZA201004400B (en) 2014-10-29
BRPI0819930A2 (pt) 2016-05-17
US20090156516A1 (en) 2009-06-18
CN101938902B (zh) 2014-07-02
TW200932755A (en) 2009-08-01
CA2707909A1 (en) 2009-06-18
AR113211A2 (es) 2020-02-19
RU2010128940A (ru) 2012-01-20
EP2230907B1 (en) 2018-05-09
EP2230907A1 (en) 2010-09-29
RU2505521C2 (ru) 2014-01-27
AR071268A1 (es) 2010-06-09
AU2008335080A1 (en) 2009-06-18
NZ586639A (en) 2011-06-30
TWI426081B (zh) 2014-02-11
AU2008335080B2 (en) 2014-06-05
CN101938902A (zh) 2011-01-05
JP2011506469A (ja) 2011-03-03
KR20100098690A (ko) 2010-09-08

Similar Documents

Publication Publication Date Title
KR101506935B1 (ko) 벤질릭 글리코시드 유도체 및 사용 방법
KR101654231B1 (ko) Ｓｇｌｔ２ 억제제의 제조방법
EP2187742B1 (en) (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylphenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol derivatives for use in the treatment of diabetes
KR101567969B1 (ko) 벤질페닐 시클로헥산 유도체 및 이의 사용 방법
US20070275907A1 (en) Glucose transport inhibitors and methods of use
AU2014201286A1 (en) Processes for the preparation of SGLT2 inhibitors
HK1142229B (en) (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylphenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol derivatives for use in the treatment of diabetes
HK1142229A (en) (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylphenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol derivatives for use in the treatment of diabetes

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20181105

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20181105